The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

Background: Stroke reduction with direct oral anticoagulants (DOACs) in atrial fibrillation
(AF) is dependent on adherence and persistence in the real-world setting. Individual study …

Objective To investigate the associations between direct oral anticoagulants (DOACs) and
risks of bleeding, ischaemic stroke, venous thromboembolism, and all cause mortality …

Background: Gastrointestinal bleeding (GIB) rates for direct oral anticoagulants (DOACs)
and warfarin have been extensively compared. However, population-based studies …

Background and Purpose—The use of oral anticoagulant therapy for stroke prevention in
atrial fibrillation has been transformed by the availability of the nonvitamin K antagonist oral …

Aims The aim of this study was to compare the risk of stroke or systemic embolism (SE) and
major bleeding in patients with atrial fibrillation (AF) using dabigatran, rivaroxaban, and …

The assessment of both thromboembolic and haemorrhagic risks and their management in
systemic amyloidosis have been poorly emphasized so far. This narrative review …

Aims To analyse the safety and efficacy of direct oral anticoagulants (DOACs) in real-world
studies including atrial fibrillation (AF) patients. Methods and results Systematic review and …

No studies have performed direct pairwise comparisons of the effectiveness and safety of
warfarin and the new oral anticoagulants (NOACs) apixaban, dabigatran, and rivaroxaban …

Background & Aims There is controversy over whether use of non-vitamin K antagonist oral
anticoagulants (NOACs) associates with increased risk of major gastrointestinal bleeding …